Home Cart Sign in  
Chemical Structure| 1422365-94-3 Chemical Structure| 1422365-94-3

Structure of Lixumistat acetate
CAS No.: 1422365-94-3

Chemical Structure| 1422365-94-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lixumistat is a derivative of metformin and an orally active AMPK activator that can alleviate age-related cognitive impairment and act as an effective oxidative phosphorylation (OXPHOS) inhibitor, suitable for solid tumor studies.

Synonyms: IM156; HL156A; HL271 acetate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lixumistat acetate

CAS No. :1422365-94-3
Formula : C15H20F3N5O3
M.W : 375.35
SMILES Code : O=C(C)O.FC(F)(OC1=CC=C(NC(NC(N2CCCC2)=N)=N)C=C1)F
Synonyms :
IM156; HL156A; HL271 acetate
MDL No. :MFCD32701937
InChI Key :AGFDCTOLSXWRDZ-UHFFFAOYSA-N
Pubchem ID :154573779

Safety of Lixumistat acetate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P264-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P362-P403+P233-P501

Related Pathways of Lixumistat acetate

epigenetics
PI3K-AKT

Isoform Comparison

Biological Activity

Description
Lixumistat acetate, a chemical derivative of Metformin, is a potent and orally active activator of AMP-activated protein kinase (AMPK), leading to increased AMPK phosphorylation. Lixumistat (acetate) mitigates aging-related cognitive impairment in animal models [1][2].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03272256 Advanced Solid Tumor PHASE1 COMPLETED 2020-07-28 CHA Bundang Medical Center, Se... More >>ongnam-si, Gyeonggi-do, 13496, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Yonsei University Severance Hospital, Seoul, Korea, Republic of Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.66mL

0.53mL

0.27mL

13.32mL

2.66mL

1.33mL

26.64mL

5.33mL

2.66mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories